News & Updates

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

Use of cycline antibiotics (CAs) is associated with an elevated risk of pseudotumour cerebri syndrome (PTCS) or papilledema, suggests a recent study. However, no statistically significant link between CA use and PTCS development is seen when accounting for confounding factors.

ACOG article 2.6

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.1

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Once-monthly subcutaneous amivantamab fares well in advanced solid tumours

In individuals with advanced solid malignancies, subcutaneous (SC) amivantamab administered once a month is associated with fewer infusion-related reactions (IRRs) and offers more convenience than the IV formulation, the phase Ib PALOMA study suggest.